2025 H1 -tulosraportti
118 päivää sitten38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
4 600
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
5,24VWAP
Alin
4,89VaihtoMäärä
44,3 8 747 932
VWAP
Ylin
5,24Alin
4,89VaihtoMäärä
44,3 8 747 932
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
22 t sitten22 t sittenMerry Christmas! Looks as if Santa invested here!
·1 päivä sittenWhat does the AI engine Grok think about the share price development for Thor Medical in the coming year? Thor Medical ASA (TRMED) has shown strong share price development throughout 2025, and as of December 23, 2025, the share closed at 5.15 NOK. This represents a significant increase from levels around 3.5–3.7 NOK earlier in the year, driven by positive news and commercial progress. Development in 2025 so far • The share has risen sharply, especially in the latter part of the year, with contributions from several strategic supply agreements (e.g., with Telix Pharmaceuticals in November and RadioMedix in December). • The company is fully financed into 2026+, and the construction of the AlphaOne factory is progressing as planned. • The Radiopharmaceutical market is growing rapidly, and Thor Medical's unique, reactor-free production of Th-228/Pb-212 positions them well as a supplier to leading players in targeted cancer therapy. Expected share price development in the coming year (2026 and beyond) Positive drivers: • Commercial launch: Full operation of the AlphaOne facility is expected in Q3 2026, with a significant capacity increase (towards a goal of 1 million patient doses annually in the long term). This could be a major catalyst and trigger significant share price upside. • More agreements and volume: Existing and new supply agreements (such as with Telix, Oncoinvent, AdvanCell, RadioMedix) will gradually generate revenue from clinical studies and later commercial products. The market for alpha-emitters is growing explosively. • Technical picture: The share has been in an upward trend, and with today's level of 5.15 NOK, momentum indicates continued positive development if milestones are reached. Analysts and forecasts: • Coverage is still limited for small biotech companies like Thor Medical, but model-based estimates point to further upside upon successful execution. • Long-term forecasts vary, but several see potential for the share price significantly above today's level upon successful commercialization (some models indicate double or more in 2–3 years' time, but this is highly speculative). Risks: • Biotech shares are highly volatile – the price can fluctuate sharply on news of production delays, partners' clinical results, or general market sentiment. • The company is still in a build-up phase with losses, and revenues will come gradually. • External factors such as regulatory approvals at customers or competition can affect. Overall, 2026 points towards becoming a breakthrough year for Thor Medical, with potential for further strong share price increase if production start and agreements deliver as expected. Today's price of 5.15 NOK already reflects a lot of positivity, but there is room for more upside. This is no investment recommendation – the share involves high risk, and you should do your own thorough analysis.
·1 päivä sitten · MuokattuCongratulations to the brave ones who are still holding TM. Now I believe that most loyal fans of TM sold out around 5kr today, it will be exciting to see if TM dips down next trading day, then the last ones will have been shaken out if it goes down. Remember that the cup and handle formation is not confirmed yet, so the chance for 6-7kr is still good. Happy weekend and Merry Christmas everyone 🥳🥳🎄🎅🤶·1 päivä sittenI think that if TM manages to keep the price above 5kr for several days with high volume, the chance of reaching 6kr first is completely real. The price usually rises before the factory shows quality and reliability but then holds stable after proven. I.e., the price can go to 6-7kr before it dips down again to around 5kr this time. It's no problem to have 100% in TM when one has xxx% in profit with SL, I think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
118 päivää sitten38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 22 t sitten22 t sittenMerry Christmas! Looks as if Santa invested here!
- ·1 päivä sittenWhat does the AI engine Grok think about the share price development for Thor Medical in the coming year? Thor Medical ASA (TRMED) has shown strong share price development throughout 2025, and as of December 23, 2025, the share closed at 5.15 NOK. This represents a significant increase from levels around 3.5–3.7 NOK earlier in the year, driven by positive news and commercial progress. Development in 2025 so far • The share has risen sharply, especially in the latter part of the year, with contributions from several strategic supply agreements (e.g., with Telix Pharmaceuticals in November and RadioMedix in December). • The company is fully financed into 2026+, and the construction of the AlphaOne factory is progressing as planned. • The Radiopharmaceutical market is growing rapidly, and Thor Medical's unique, reactor-free production of Th-228/Pb-212 positions them well as a supplier to leading players in targeted cancer therapy. Expected share price development in the coming year (2026 and beyond) Positive drivers: • Commercial launch: Full operation of the AlphaOne facility is expected in Q3 2026, with a significant capacity increase (towards a goal of 1 million patient doses annually in the long term). This could be a major catalyst and trigger significant share price upside. • More agreements and volume: Existing and new supply agreements (such as with Telix, Oncoinvent, AdvanCell, RadioMedix) will gradually generate revenue from clinical studies and later commercial products. The market for alpha-emitters is growing explosively. • Technical picture: The share has been in an upward trend, and with today's level of 5.15 NOK, momentum indicates continued positive development if milestones are reached. Analysts and forecasts: • Coverage is still limited for small biotech companies like Thor Medical, but model-based estimates point to further upside upon successful execution. • Long-term forecasts vary, but several see potential for the share price significantly above today's level upon successful commercialization (some models indicate double or more in 2–3 years' time, but this is highly speculative). Risks: • Biotech shares are highly volatile – the price can fluctuate sharply on news of production delays, partners' clinical results, or general market sentiment. • The company is still in a build-up phase with losses, and revenues will come gradually. • External factors such as regulatory approvals at customers or competition can affect. Overall, 2026 points towards becoming a breakthrough year for Thor Medical, with potential for further strong share price increase if production start and agreements deliver as expected. Today's price of 5.15 NOK already reflects a lot of positivity, but there is room for more upside. This is no investment recommendation – the share involves high risk, and you should do your own thorough analysis.
- ·1 päivä sitten · MuokattuCongratulations to the brave ones who are still holding TM. Now I believe that most loyal fans of TM sold out around 5kr today, it will be exciting to see if TM dips down next trading day, then the last ones will have been shaken out if it goes down. Remember that the cup and handle formation is not confirmed yet, so the chance for 6-7kr is still good. Happy weekend and Merry Christmas everyone 🥳🥳🎄🎅🤶·1 päivä sittenI think that if TM manages to keep the price above 5kr for several days with high volume, the chance of reaching 6kr first is completely real. The price usually rises before the factory shows quality and reliability but then holds stable after proven. I.e., the price can go to 6-7kr before it dips down again to around 5kr this time. It's no problem to have 100% in TM when one has xxx% in profit with SL, I think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
4 600
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
5,24VWAP
Alin
4,89VaihtoMäärä
44,3 8 747 932
VWAP
Ylin
5,24Alin
4,89VaihtoMäärä
44,3 8 747 932
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: Quartr, FactSet
2025 H1 -tulosraportti
118 päivää sitten38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 22 t sitten22 t sittenMerry Christmas! Looks as if Santa invested here!
- ·1 päivä sittenWhat does the AI engine Grok think about the share price development for Thor Medical in the coming year? Thor Medical ASA (TRMED) has shown strong share price development throughout 2025, and as of December 23, 2025, the share closed at 5.15 NOK. This represents a significant increase from levels around 3.5–3.7 NOK earlier in the year, driven by positive news and commercial progress. Development in 2025 so far • The share has risen sharply, especially in the latter part of the year, with contributions from several strategic supply agreements (e.g., with Telix Pharmaceuticals in November and RadioMedix in December). • The company is fully financed into 2026+, and the construction of the AlphaOne factory is progressing as planned. • The Radiopharmaceutical market is growing rapidly, and Thor Medical's unique, reactor-free production of Th-228/Pb-212 positions them well as a supplier to leading players in targeted cancer therapy. Expected share price development in the coming year (2026 and beyond) Positive drivers: • Commercial launch: Full operation of the AlphaOne facility is expected in Q3 2026, with a significant capacity increase (towards a goal of 1 million patient doses annually in the long term). This could be a major catalyst and trigger significant share price upside. • More agreements and volume: Existing and new supply agreements (such as with Telix, Oncoinvent, AdvanCell, RadioMedix) will gradually generate revenue from clinical studies and later commercial products. The market for alpha-emitters is growing explosively. • Technical picture: The share has been in an upward trend, and with today's level of 5.15 NOK, momentum indicates continued positive development if milestones are reached. Analysts and forecasts: • Coverage is still limited for small biotech companies like Thor Medical, but model-based estimates point to further upside upon successful execution. • Long-term forecasts vary, but several see potential for the share price significantly above today's level upon successful commercialization (some models indicate double or more in 2–3 years' time, but this is highly speculative). Risks: • Biotech shares are highly volatile – the price can fluctuate sharply on news of production delays, partners' clinical results, or general market sentiment. • The company is still in a build-up phase with losses, and revenues will come gradually. • External factors such as regulatory approvals at customers or competition can affect. Overall, 2026 points towards becoming a breakthrough year for Thor Medical, with potential for further strong share price increase if production start and agreements deliver as expected. Today's price of 5.15 NOK already reflects a lot of positivity, but there is room for more upside. This is no investment recommendation – the share involves high risk, and you should do your own thorough analysis.
- ·1 päivä sitten · MuokattuCongratulations to the brave ones who are still holding TM. Now I believe that most loyal fans of TM sold out around 5kr today, it will be exciting to see if TM dips down next trading day, then the last ones will have been shaken out if it goes down. Remember that the cup and handle formation is not confirmed yet, so the chance for 6-7kr is still good. Happy weekend and Merry Christmas everyone 🥳🥳🎄🎅🤶·1 päivä sittenI think that if TM manages to keep the price above 5kr for several days with high volume, the chance of reaching 6kr first is completely real. The price usually rises before the factory shows quality and reliability but then holds stable after proven. I.e., the price can go to 6-7kr before it dips down again to around 5kr this time. It's no problem to have 100% in TM when one has xxx% in profit with SL, I think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
4 600
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
5,24VWAP
Alin
4,89VaihtoMäärä
44,3 8 747 932
VWAP
Ylin
5,24Alin
4,89VaihtoMäärä
44,3 8 747 932
Välittäjätilasto
Dataa ei löytynyt